期刊文献+

他汀类药物在缺血性卒中防治中的作用 被引量:4

Roles of statins in the prevention and treatment of ischemic stroke
原文传递
导出
摘要 目前,他汀类药物是防治心脑血管病的最重要药物之一.近年来,大量临床研究和汇总分析证实,他汀类药物能有效降低缺血性卒中的发生和复发风险.文章就他汀类药物在缺血性卒中的一级预防、急性期治疗和二级预防中的应用进行了综述. Currently,statins are one of the most important medications for the prevention and treatment of cardio-cerebrovascular diseases.In recent years,a large number of clinical studies and metaanalyses have confirmed that statins can effectively reduce the risks of the occurrence and recurrence of ischemic stroke.This article reviews the applications of statins in the primary prevention,acute treatment,and the secondary prevention of ischemic stroke.
出处 《国际脑血管病杂志》 北大核心 2013年第12期918-922,共5页 International Journal of Cerebrovascular Diseases
基金 国家自然科学基金(81100870,81201078)
关键词 卒中 脑缺血 羟甲基戊二酰基COA还原酶抑制剂 Stroke Brain Ischemia Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • 相关文献

参考文献45

  • 1Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Nackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012, 380: 581-590.
  • 2Johnson-Anuna LN, Eckert GP, Franke C, et al. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem, 2007, 101 : 77-86.
  • 3Landmesser U, Bahlmann F, Mueller M, et al. Sinlvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation, 2005,111:2356-2363.
  • 4Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation, 2004, 109(21 Suppl 1): 1142-1148.
  • 5Endres M. Statins and stroke. J Cereb Blood Flow Metab, 2005, 25: 1093-1110.
  • 6Fisher M, Moonis M. Neuroprotective effects of statirls: evidence from preclinical and clinical studies. Curr Treat Options Cardiovasc Med, 2012, 14: 252-259.
  • 7Catapano AL, Reiner Z, De Backer G, et al; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011, 217: 3-46.
  • 8Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344: 1383-1389.
  • 9Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996, 335: 1001-1009.
  • 10LaRosa JC, Grundy SM, Kastelein JJ, et al; Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a posthoc analysis of the treating to new targets [ TNT ] study). Am J Cardiol, 2007, 100: 747-752.

二级参考文献63

共引文献1003

同被引文献20

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部